The Israeli biotech company Immunai (Immunai) has announced the raising of Round B in the amount of $ 215 million at a value of over $ 1 billion. The company has developed a system based on a combination of artificial intelligence technologies and immunology, which allows “to accelerate the development of new drugs targeting the fight against cancer.”
The raising was led by Koch Disruptive Technologies, with the participation of investors: Talos VC, 8VC, Alexandria Venture Investments, Piedmont and ICON. This is the company’s second round of capital raising this year. Earlier this year, Immunai reported raising $ 60 million. The current fundraiser brings the company’s total fundraising to $ 295 million since its inception.
“In the past year, we have made significant progress toward our core mission – understanding the immune system, which is essential to understanding our health,” said the company’s CEO, Dr. Noam Solomon. “The current investment will be used to further develop the actuarial platform we have built, which allows pharmaceutical and biotechnology companies to accelerate the drug development process and assess their market potential,” he added.
Immunai mapped the human immune system and created AMICA, the largest immuno-clinical cell pool of its kind in the world, from which, using a sophisticated computational learning engine, immunai identifies new mechanisms of action that explain diseases and various drug development goals.
Immunai has collaborations with leading biotechnology companies and academic institutions, including Fortune 100 pharmaceutical companies and leading academic institutions: Harvard, Stanford, Memorial Sloan Kettering and Baylor College of Medicine.
Immunai was founded in 2018 by Dr. Noam Solomon, who serves as the company’s CEO, and Luis Wallach, who serves as VP of technology. The two are graduates of the faculties of mathematics and computer science at MIT and Harvard.
The two were joined as founders by Prof. Ansoman Stephanie of Stanford University, an immunologist, Dr. Daniel Wells, a computational biologist at the Parker Institute for Cancer Research, and the immunologist Prof. Dan Littman. Also in July this year, Robert Langer, one of the founders of the modern pharmaceutical company and one of the leading chemical engineers of the 21st century, joined the company’s board of directors.